Hypothesis: Pharmacological autophagy activators like rapamycin, spermidine, and urolithin A may produce their anti-aging effects not by clearing senescent cells or restoring youthful tissue homeostasis, but by redundantly fueling the autophagy-dependent survival circuit already running in these cells—making the siege more tolerable without actually lifting it. The apparent rejuvenation seen in organismal studies might mainly come from non-senescent cell populations or from immune modulation, while senescent cells persist with enhanced metabolic resilience.

Mechanistic Reasoning: Senescent cells have co-opted autophagy from a damage-control pathway into a resource-allocation survival system. This creates a self-reinforcing loop where mTORC1 maintains elevated basal autophagy, which continuously supplies amino acids to sustain mTORC1 and SASP production [10.1083/jcb.201610113]. The result is a metabolic dependency—but dependencies only become therapeutic vulnerabilities if the intervention disrupts rather than supplements the pathway. When a system is already running at maximal autophagic flux to survive starvation, adding more autophagy activation may be redundant. The siege is already being managed as well as it can be. Instead, the intervention's off-target or immune-modulatory effects might actually drive any observed benefit. Importantly, senescent cells show vulnerability to both autophagy blockade (chloroquine, bafilomycin) and hyperactivation (cardiac glycosides), suggesting the system operates near a critical threshold [10.1111/acel.13447]. Mild autophagy enhancement, however, may fall into a "Goldilocks zone"—it neither disrupts the loop nor triggers death, instead providing just enough metabolic relief to extend senescent cell persistence.

Testable Prediction: In organismal studies, the anti-aging benefits of autophagy activators should correlate inversely with senescent cell burden. If I'm right, interventions that robustly activate autophagy should reduce measurable senescent cell markers less than interventions that block autophagy, yet still improve healthspan through effects on proliferating or post-mitotic cells. More directly, pre-treatment with autophagy activators should confer partial resistance to subsequent senolytic challenge (dasatinib + quercetin), because the enhanced autophagy buffer makes senescent cells more metabolically stable before the proteotoxic stress of senolytic treatment.

Falsifiability: If autophagy activators consistently reduce senescent cell abundance—measured via p16^INK4a or SA-β-gal staining—in tissues where they improve function, the hypothesis is falsified. That pattern would mean the intervention genuinely clears the siege rather than subsidizing it.